Evaluation of effect of OMEGA3 supplement on the incidence of gestational diabetes mellitus in high risk pregnancies for diabetes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200505047306N1

Enrollment

Registered

2020-05-23

Start date

2020-05-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes. Gestational diabetes mellitus

Interventions

Intervention 1: In omega-3 groups, one gram omega-3 tablet containing eicosapentaenoic acid EPA and docosahexaenoic acid DHA will be used daily for 6 weeks. Intervention 2: Control group: The most com

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women 18 to 22 weeks diagnosed with high-risk pregnancies

Exclusion criteria

Exclusion criteria: Diagnosis of overt diabetes or use of insulin at baseline (FBS> = 105 or 2 hpp> = 120) Dissatisfaction with the company in studying the history of allergies to omega-3 Unable to continue taking the drug due to digestive problems or allergic reactions

Design outcomes

Primary

Measure	Time frame
The incidence of gestational diabetes in the Omega-3 group. Timepoint: In the time before and 6 weeks after taking the supplement. Method of measurement: Lab report.	—

Secondary

Measure	Time frame
Blood sugar levels in the supplement and placebo groupplacebo group. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.;Insulin levels in the placebo and omega groupsinsulin levels in both groups. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.;HOMA-IR and HOMA-B in two groups of omega-3 and placebo supplements. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.;Fat profile in two groups of omega-3 and placebo supplements. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.	—

Measure

Time frame

Blood sugar levels in the supplement and placebo groupplacebo group. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.;Insulin levels in the placebo and omega groupsinsulin levels in both groups. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.;HOMA-IR and HOMA-B in two groups of omega-3 and placebo supplements. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.;Fat profile in two groups of omega-3 and placebo supplements. Timepoint: In the time before and 6 weeks after consumption. Method of measurement: Lab report.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZolykha Atarod

Mazandaran University of Medical Sciences

Z.atarod64@yahoo.com+98 11 3336 5724

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026